sj-pdf-1-tan-10.1177_1756286420987941 – Supplemental material for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

Kappos, Ludwig; Cohan, Stanley; Arnold, Douglas L.; Robinson, Randy R.; Holman, Joan; Fam, Sami; Parks, Becky; Xiao, Shan; Castro-Borrero, Wanda

doi:10.25384/SAGE.14131909.v1

sj-pdf-1-tan-10.1177_1756286420987941.pdf (299.12 kB)

sj-pdf-1-tan-10.1177_1756286420987941 – Supplemental material for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

journal contribution

posted on 2021-02-28, 13:07 authored by Ludwig Kappos, Stanley Cohan, Douglas L. Arnold, Randy R. Robinson, Joan Holman, Sami Fam, Becky Parks, Shan Xiao, Wanda Castro-Borrero

Supplemental material, sj-pdf-1-tan-10.1177_1756286420987941 for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination by Ludwig Kappos, Stanley Cohan, Douglas L. Arnold, Randy R. Robinson, Joan Holman, Sami Fam, Becky Parks, Shan Xiao and Wanda Castro-Borrero in Therapeutic Advances in Neurological Disorders